Early detection and intervention of cancer and other diseases is crucial to optimizing outcomes for patients. That, said James Howard-Tripp, is the reason StageZero Life Sciences was created.
“We can’t continue to find disease when it’s symptomatic and late,” he said. “The outcomes are horrendous. You have to find disease early if you want to change things.”
StageZero Life Sciences is an integrated health care company based in Canada with a U.S. headquarters in Richmond. The company recently announced that patients can access its innovative technology, which aims to provide early detection of multiple cancers through a single sample of blood.
The multi-cancer test, called Aristotle, is based on a proprietary mRNA technology platform. It plans to simultaneously screen for specific cancers like colorectal, stomach, breast, ovarian, liver and prostate, Howard-Tripp, company chairman and chief executive officer, said.
The test uses blood to identify changes in a person’s…
Read the full story from the Washington Business Journal.
